Stock Price & Analysis

Based on the recent data and news, I'll provide a comprehensive analysis of whether to buy or sell BDX stock.

Recent Major Development: BDX announced plans to split from its bioscience and diagnostic solutions arms. The separation will create:

• New BD: Expected FY2024 revenue of $17.8B (Medical Essentials, Connected Care, BioPharma Systems, and Interventional)
• Separated Business: Expected FY2024 revenue of $3.4B (Biosciences and Diagnostic Solutions)

Technical Analysis:

• Current price at $227.43 shows bearish momentum
• RSI(14) at 40.89 indicates neutral but approaching oversold territory
• MACD shows bearish divergence with -2.66
• Price is trading below both 60-day SMA ($230.46) and 200-day SMA ($232.12)
• Fibonacci support levels: S1 at $222.94, S2 at $219.95
• Fibonacci resistance levels: R1 at $232.65, R2 at $235.64

Fundamental & Analyst Views:

• Strong Buy consensus with average price target of $273.33, implying 20.3% upside
• Recent price targets:
  • Barclays: $278 (Buy)
  • Morgan Stanley: $280 (Buy)
  • TD Cowen: $260 (Hold)

Recent Performance:

• Q1 FY25 results beat estimates:
  • EPS: $3.43 vs $2.98 expected
  • Revenue: $5.17B vs $5.1B expected
• Updated FY25 guidance:
  • Revenue: $21.7B-$21.9B (lowered)
  • Adjusted EPS: $14.30-$14.60 (raised lower end)

Sell Factors:

• Negative insider sentiment with increased selling
• Stock trading below key moving averages
• Lowered revenue guidance
• Near-term uncertainty due to upcoming separation

Buy Factors:

• Strong analyst consensus
• Significant upside potential
• Strategic separation could unlock shareholder value
• Consistent earnings beats
• Raised EPS guidance

Conclusion: SELL Despite strong analyst support, the technical indicators and near-term catalysts suggest selling BDX at current levels. The stock's bearish momentum, negative insider sentiment, and uncertainty around the business separation create downside risks. Better entry points may emerge after the stock finds support or shows clear technical reversal signals.

Based on the provided data and recent market developments, here's a comprehensive price prediction analysis for BDX stock in 2025:

Technical Analysis

The stock is currently trading at $227.43, showing a bearish trend in the near term. The stock has formed a clear downward channel since early February 2025, with key support levels at $218.75 (52-week low) and resistance at $251.99 (52-week high).

Fundamental Catalysts

1. Strategic Separation Plan

• BDX announced plans to separate its Biosciences and Diagnostic Solutions business
• New BD will become a pure-play MedTech company with expected FY2024 revenue of $17.8 billion
• Separation targeted for completion in fiscal 2026

2. Strong Financial Performance

• Q1 FY25 adjusted EPS of $3.43, beating consensus of $2.98
• Revenue guidance for FY25: $21.7-21.9 billion
• Adjusted EPS guidance: $14.30-14.60

Analyst Price Targets

Firm	Price Target	Upside from Current
Barclays	$278.00	22.2%
Morgan Stanley	$280.00	23.1%
Average Consensus	$273.33	20.3%

2025 Price Prediction

Based on current market conditions and catalysts:

• Base Case ($275): Most likely scenario (60% probability)

  • Successful execution of separation plan
  • Meeting FY25 guidance
  • Continued operational improvements

• Bull Case ($290): Optimistic scenario (25% probability)

  • Exceeding earnings expectations
  • Faster-than-expected synergy realization
  • Improved market conditions

• Bear Case ($240): Conservative scenario (15% probability)

  • Integration challenges
  • Market volatility
  • Macro headwinds

Conclusion

The stock is likely to reach $275 by end of 2025, representing a 20.9% upside from current levels. This prediction is supported by:

• Strong analyst consensus
• Strategic transformation initiatives
• Solid fundamental performance
• Historical trading patterns

The S1 support level for BDX Stock is $223.1 ,The R1 resistant level for BDX Stock is $230.86.

As of the end of day on 2025-02-26, the price of BDX Stock was $229.06.

The target price for BDX Stock according to analyst rating is 272.82, with the highest price target at 290.00 and the lowest at 245.00. Analysts have a Strong Buy rating on BDX Stock overall.

The market cap of BDX is $66.1B.

Based on the provided data and recent developments, let me analyze whether BDX is overvalued:

Technical Analysis The stock is currently trading at $242.09, below its 200-day moving average of $232.12, suggesting some technical weakness. The RSI-14 at 40.89 indicates the stock is approaching oversold territory but not yet there.

Valuation Metrics

• Current P/E ratio: 52.36x (Q4 2023)
• EV/EBITDA: 17.15x
• Price/Sales: 3.63x
• Price/Book: 2.78x

These multiples are relatively high compared to the medical technology sector average, suggesting premium valuation.

Recent Catalysts BDX recently announced plans to split from its bioscience and diagnostic solutions arms. This strategic separation is expected to:

• Create two focused companies
• New BD will have revenue of $17.8B
• Separated business will have revenue of $3.4B
• Completion expected in 2026

Analyst Consensus Wall Street remains bullish despite current valuation:

• Strong Buy consensus rating with 10 Buys, 2 Holds
• Average price target of $273, implying 11.4% upside
• Recent price target from Barclays at $278

Conclusion BDX appears moderately overvalued based on:

1. Premium valuation multiples versus peers
2. Trading below key technical levels
3. Upcoming business separation creating near-term uncertainty
4. However, strong analyst support and strategic initiatives provide some justification for the premium valuation

Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, and others. The Company's BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a wide range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, and pharmaceutical systems. The Company's BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a broad range of infectious diseases, healthcare-associated infections and cancers. The Company's BD Interventional segment provides vascular, urology, oncology and surgical specialty products.

Based on the provided data and recent developments, here's a price prediction analysis for BDX stock by 2030:

Base Case Scenario: $274-280 (2030) BDX is expected to reach this range based on several key factors:

• Strong analyst consensus with a current price target of $273, indicating immediate upside potential
• Planned strategic separation of Biosciences and Diagnostic Solutions business by 2026
• Consistent revenue growth with FY25 guidance of $21.7-21.9 billion

Growth Catalysts:

• The separation into two focused entities will likely unlock shareholder value
• New BD will become a pure-play MedTech company with projected revenue of $17.8 billion
• Strong operational execution with margin expansion and robust cash flow generation

Key Supporting Metrics:

• Q1 FY25 showed 9.6% revenue growth and 28% adjusted EPS increase
• Healthy dividend yield of 1.58%
• Consistent margin improvements with adjusted gross margin reaching 54.8%

BDX has a total of 73000 employees.